Skip to main content

Media Center

Latest News

This filter choice is only applicable to the "Article" news type.
June 12, 2026
Washington, D.C. — Today, House Judiciary Committee Ranking Member Jamie Raskin (MD-08), Congresswoman Deborah Ross (NC-02), and Congressman Ro Khanna (CA-17) demanded answers on a Bureau of Prison (BOP) policy change that grants the Attorney General new authority over inmate placement decisions. This previously unreported policy change comes after Ghislaine Maxwell was moved to a minimum security prison, often referred to as ‘Club Fed,’ despite being ineligible for this transfer as a convicted sex offender.

June 10, 2026
WASHINGTON – Rep. Jamie Raskin (MD-08), Ranking Member of the House Judiciary Committee, Rep. Joe Morelle (NY-25), the Ranking Member of the Committee on House Administration, and Rep. Robert Garcia (CA-42), Ranking Member of the House Committee on Oversight and Government Reform, demanded a transcribed interview with WinRed CEO Ryan Lyk following concerns about evidence that WinRed may be processing illegal contributions from foreign sources.

June 10, 2026
Washington, D.C. (June 10, 2026)—Today, Rep. Jamie Raskin, Ranking Member of the House Judiciary Committee, and Rep. Jerrold Nadler, Ranking Member of the Subcommittee on the Administrative State, Regulatory Reform, and Antitrust, led Democrats in calling out how corrupt, politically driven Trump Administration antitrust decisions are accelerating media consolidation, complicating sports broadcasting markets, and forcing consumers to pay more for fewer viewing options.

June 10, 2026
Washington, D.C. (June 10, 2026)—Today, Rep. Jamie Raskin, Ranking Member of the House Judiciary Committee, delivered opening remarks at a subcommittee hearing examining how politically driven and corrupt Trump Administration antitrust enforcement is enabling media consolidation, raising costs for consumers, and harming competition in broadcasting markets.

June 10, 2026
Washington, D.C. (June 10, 2026)— Today, Rep. Jerrold Nadler, Ranking Member of the Subcommittee on the Administrative State, Regulatory Reform, and Antitrust, delivered opening remarks at the Subcommittee on the Administrative State, Regulatory Reform, and Antitrust hearing on how Trump Administration antitrust policies are increasing television streaming costs, particularly for sports fans.

June 10, 2026
Washington, D.C. (June 10, 2026)—Today, Rep. Jamie Raskin, Ranking Member of the House Judiciary Committee, delivered opening remarks at a Committee on House Administration hearing on Republicans’ vindictive and partisan investigation into ActBlue, a donation platform used by Democratic candidates around the country, while they ignore far more significant and troubling fraud allegations surrounding Republican platform WinRed.

June 9, 2026
Washington, D.C. (June 9, 2026)— Today, Rep. Jamie Raskin, Ranking Member of the House Judiciary Committee, led Committee Democrats in exposing House Republicans’ baseless charges against the Southern Poverty Law Center (SPLC) for what it is: a blatant attempt to intimidate civil rights institutions and prosecute political enemies.

June 9, 2026
Washington, D.C. (June 9, 2026)—Today, Rep. Jamie Raskin, Ranking Member of the House Judiciary Committee, delivered opening remarks at a hearing slamming Republicans’ baseless assault on the Southern Poverty Law Center (SPLC) in the aftermath of a vindictive Department of Justice (DOJ) prosecution aimed at silencing civil rights defenders while emboldening extremist groups.

June 9, 2026

Washington, D.C. (June 9, 2026)— Today, Rep. Jamie Raskin, Ranking Member of the House Committee on the Judiciary, issued the following statement after reauthorization of Section 702 of the Foreign Intelligence Surveillance Act (FISA) appeared to have stalled in the U.S. Senate.


June 4, 2026
Washington, D.C. (June 4, 2026)—Today, Rep. Hank Johnson, Ranking Member of the Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet, delivered opening remarks at a subcommittee hearing on how to best encourage innovation in the medical field while still maintaining low drug prices.